Fractyl Health, Inc.
GUTSHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeFractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. At a $14.3M market cap, Fractyl Health, Inc. ranks as a micro-cap company within healthcare. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Market Cap
$14.3M
Beta
2.42
P/E (TTM)
—
P/E (Fwd)
-0.29
EPS (TTM)
$-10.09
EPS (Fwd)
$-3.67
ROE
—
ROA
-74.6%
Cash
$47.1M
Total Debt
$60.7M
Free CF
-$48.4M
52W Change
-93.5%
Annual Financials
Cash vs Debt
Where GUTS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GUTS finished 82.35% below its 150-day moving average ($7.82) and 84.56% below its 200-day moving average ($8.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GUTS overbought or oversold?
At the October 20, 2026 close, GUTS's RSI(14) was 10.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $47.1M in cash, though total debt stands at $60.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$48.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
With a beta above 1.5, GUTS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing GUTS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.